We appreciate the comments by Le Large and colleagues regarding our article describing metastatic pancreatic ductal adenocarcinoma (PDAC) microenvironment subtypes using proteomics (1). As they point out, our study revealed four proteomic subtypes utilizing bulk PDAC liver metastases, identified subtype-specific protein associations with survival, and determined that subtypes are predictive of response to chemotherapy.

Our study is unique in its analysis of metastatic PDAC, which is important to the majority of patients who present with advanced disease and are reliant upon chemotherapy. Disseminated disease has largely been unexplored by previous subtyping efforts, which have focused primarily on treatment-naïve early-stage primary tumors. Our work was possible because of our unique biorepository of PDAC rapid autopsy samples that are of outstanding quality for molecular assays as well as generation of patient-derived xenograft (PDX) models (https://pdmr.cancer.gov/) and organoids (2, 3). Importantly, the correlation we observed between the...

You do not currently have access to this content.